Ligand Pharma (LGND) Stock Target Raised After XOMA Acquisition
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowBank of America (BofA) has raised its price target for Ligand Pharmaceuticals (LGND) following the company's acquisition of XOMA Corporation. This move reflects confidence in the combined entity's potential to enhance market presence. No specific new price target was provided in the announcement. The acquisition is expected to have a positive impact on Ligand's growth trajectory, which may influence investor sentiment and market performance moving forward.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Bank of America Corporation (BAC)
Bank of America is one of the largest U.S. banks, offering consumer banking, wealth management, and investment banking.
The Financials sector covers banks, insurers and capital-markets firms at the center of the economy.
Earlier BAC news
- Nvidia (NVDA) stock catalyst potential highlighted by BofA analysis
- Bank of America Cuts Pentair (PNR) Price Target to $88
- Air Products (APD) Price Target Raised to $303 by Bank of America
- JPMorgan (JPM) hires two top tech bankers from Bank of America
- Kevin Warsh Suggests New Inflation Metrics Amid Federal Reserve Hearing
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
